Resveratrol synergizes with cisplatin to suppress osteosarcoma U2-OS cells via up-regulating Cx43 and inducing ROS-dependent apoptosis Authors: Hong-Bo Xing, Hao-Yu Li, Gui-Zhou Zheng, Qi-Hao Zhang, Lei Zhai, Xiang Wu, Shi-Xin Du, Xue-Dong Li Published: 2025 ABSTRACT AbstractBackgroundResveratrol (Res), a plant-derived polyphenol, exerts synergistic effects when combined with various chemotherapeutic drugs, enhancing the antitumor activity of traditional chemotherapy. However, whether Res combined with cisplatin (CDDP) produces a synergistic inhibitory effect on osteosarcoma cell growth and its underlying mechanisms remain unclear.MethodsWe investigated the responses of U2-OS cells to Res, CDDP, or their combination using Cell Counting Kit-8 (CCK-8) for proliferation, flow cytometry for apoptosis, wound healing assays for migration, and Transwell assays for invasion. The effects of the two drugs on Wnt/β-catenin signaling were analyzed via quantitative real-time PCR (qRT-PCR) and western blotting. Additionally, the relationship between Cx43 and Wnt/Wnt/β-catenin signaling was explored by knocking down Cx43 using lentiviral infection.ResultsThe combination of Res and CDDP exhibited greater cytotoxicity against osteosarcoma U2-OS cells than either drug alone, and this effect was synergistic as determined by the Chou-Talalay equation. Cx43 knockdown attenuated the strong antitumor effect of the Res + CDDP combination and restored Wnt/β-catenin signaling activity. Furthermore, the Res + CDDP combination generated more reactive oxygen species (ROS) than individual treatments, inducing ROS-dependent apoptosis, which was blocked by N-acetylcysteine (NAC).ConclusionsRes combined with CDDP exerts a synergistic inhibitory effect on osteosarcoma by upregulating Cx43 and inducing ROS-dependent apoptosis. This study may provide a novel therapeutic strategy and potential clinical applications for osteosarcoma treatment.Keywords: Resveratrol, Cx43, Combination, Osteosarcoma, Wnt/β-catenin Introduction Accounting for approximately 60% of malignant bone tumors, osteosarcoma is the most common primary malignant bone tumor in children, adolescents, and young adults, causing local destruction by producing malignant osteoid or immature bone. Although the 5-year overall survival rate for patients with localized osteosarcoma is approximately 65% to 70%, that for patients with metastasis or recurrence drops to 25% or less [1, 2]. The primary management strategies for osteosarcoma include surgery, neoadjuvant chemotherapy, and radiotherapy. Cisplatin (CDDP) is one of the most common and efficacious chemotherapeutic drugs used in osteosarcoma treatment; it primarily forms bivalent adducts with nucleophilic sites on purines in DNA, leading to intra-strand crosslinks between adjacent purines, DNA damage, and subsequent tumor cell apoptosis [3]. However, its clinical application is limited by severe side effects and the development of chemoresistance [4]. Thus, there is an urgent need to reduce CDDP toxicity and enhance its antitumor activity through novel, more effective therapeutic approaches to improve osteosarcoma treatment outcomes. Resveratrol (Res), a classic natural polyphenolic phytoalexin, is widely present in various plants and traditional Chinese medicines (e.g., Polygonum cuspidatum, grape skin, white snake vine, rhubarb, and peanuts). It has been shown to boost immunity and exert anti-inflammatory, antibacterial, antioxidant, and cardiovascular protective effects [5, 6]. Additionally, accumulating evidence indicates that Res possesses anticancer activity, potently inhibiting the initiation and progression of multiple cancers, including breast, prostate, colorectal, and gastric cancers [7]. One mechanism underlying its antiproliferative effects involves the induction of reactive oxygen species (ROS), which can upregulate the expression of apoptosis-related genes [8]. ROS are normal by-products of cellular metabolism and play critical roles in signal transduction, cellular responses, and damage repair [9]. Compared with normal cells, cancer cells exhibit intrinsically higher ROS levels and are under oxidative stress due to hypermetabolism and an imbalanced redox status. It has been proposed that cancer cells are unable to tolerate additional oxidative stress, making them sensitive to agents that further increase ROS levels [10]. Therefore, enhancing ROS production represents a promising therapeutic strategy for cancer, as exemplified by chemotherapeutic agents such as rapamycin, pachymic acid, and erianin [11–13]. Several studies have demonstrated that Res can induce ROS production and trigger the expression of apoptosis-related proteins in various cancer cells [14–16]. Given that cancer cells cannot cope with excessive oxidative stress, Res may be a suitable candidate for combination therapy in osteosarcoma. Res regulates multiple proteins and signaling pathways in cells, including connexin 43 (Cx43) and the Wnt/β-catenin signaling pathway. Cx43 is a key component of gap junction intercellular communication (GJIC), which maintains the exchange of intercellular information, materials, and energy, and regulates biological behaviors such as cell proliferation, differentiation, and apoptosis. More importantly, Cx43 plays a critical role in the initiation, growth, metastasis, and prognostic prediction of many tumors, including breast and colorectal cancers [17–19]. Cx43 and other connexin isoforms are frequently downregulated in tumors, leading to loss of GJIC, which impairs the body’s ability to monitor cells and exchange information. Studies have shown that certain drugs, such as dioscin [20] and Qigesan [21], enhance the inhibition of tumor cell proliferation and invasion by upregulating Cx43/GJIC expression, whereas downregulating Cx43/GJIC via small interfering RNA-mediated silencing of Cx43 can increase tumor malignancy [22, 23]. Thus, Cx43 often exerts a tumor-suppressive role in many cancers. The Wnt/β-catenin signaling pathway is also critical for cell growth, motility, and differentiation. Wnt signal transduction induces β-catenin translocation to the nucleus, where it activates T-cell factor (TCF)/lymphoid enhancer factor transcription factors and upregulates the transcription of downstream genes, including c-Myc, cyclin D1, and matrix metalloproteinases (MMPs) [24]. Studies have demonstrated that aberrant activation of the Wnt/β-catenin pathway can drive excessive cell proliferation, contributing to the development of multiple malignancies such as malignant melanoma, colorectal cancer, gastric cancer, liver cancer, and breast cancer [25]. Abnormal Wnt signaling activation is also a hallmark of various bone and soft-tissue sarcomas [26]. Therefore, Cx43 and the Wnt/β-catenin signaling pathway are considered potential targets for developing new anticancer agents for osteosarcoma. Res is a multi-target agent with low cost and toxicity that can regulate both Cx43 and Wnt signaling pathways. More importantly, numerous studies have confirmed that when Res is combined with various chemotherapeutic drugs (e.g., 5-fluorouracil, gefitinib, and gemcitabine), anticancer activity is significantly enhanced [27–29]. Based on these characteristics of Res, we hypothesized that combining Res with CDDP could synergistically inhibit osteosarcoma U2-OS cells. In this study, we demonstrate that Res and CDDP exert a synergistic inhibitory effect on osteosarcoma U2-OS cells. Res (9 µg/ml) upregulates Cx43 to inhibit Wnt/β-catenin signaling and enhance tumor cell sensitivity to CDDP, an effect that can be blocked by Cx43 silencing. Additionally, the combination of the two drugs generates more ROS than either treatment alone. Thus, the combination of Res and CDDP may represent an effective and valuable new therapeutic strategy for osteosarcoma treatment. Materials and methods Cell culture Human osteosarcoma U2-OS cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), where they were characterized by DNA fingerprinting, isozyme detection, mycoplasma testing, and cell viability assays. Cells were cultured in RPMI 1640 medium (Gibco, NY, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, NY, USA) and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin) in a 5% CO2 humidified atmosphere at 37 °C. All cell lines underwent cytogenetic testing and authentication prior to freezing. Each vial of frozen cells was thawed and maintained for a maximum of 12 weeks. Resveratrol (Res) was purchased from Sigma-Aldrich Chemical Co. (CA, USA) and dissolved in DMSO. Cisplatin (CDDP) was purchased from Sigma-Aldrich and dissolved in normal saline. N-acetylcysteine (NAC) and 2′,7′-dichlorofluorescein diacetate (DCFH-DA) were also obtained from Sigma-Aldrich. Lentivirus infection To achieve specific Cx43 knockdown and exclude potential off-target effects, two independent lentiviral vectors (H1/GFP&Puro) encoding Cx43 short-hairpin RNAs (shRNAs) were constructed by GenePharma (Suzhou, China): shCx43-1: Target sequence 5’-GAACCTACATCATCAGTAT-3’ (corresponding to nucleotide positions 345–363 of Cx43 mRNA; GenBank accession No.: NM_010288.3). shCx43-2: Target sequence 5’-GCTGCTGGTGATGCTGCTT-3’ (corresponding to nucleotide positions 512–530 of Cx43 mRNA; GenBank accession No.: NM_010288.3). A vector containing a scrambled non-targeting control shRNA (NTC; sequence 5’-CAACAAGATGAAGAGCACCAA-3’) was also constructed to eliminate non-specific effects induced by lentiviral infection or puromycin selection. The virus titer used for infection was 109 TU/ml. U2-OS cells were inoculated into 6-well plates at a density of 4 × 105 cells per well and allowed to attach overnight. Cells were then cultured in medium containing 5 µg/ml polybrene (Sigma, CA, USA) and incubated for 1 h prior to the addition of lentivirus (shCx43-1, shCx43-2, or NTC) at a multiplicity of infection (MOI) of 25–125. The incubation medium was replaced with fresh medium 24 h post-infection, and stably infected cells were selected in medium containing 1 µg/ml puromycin (Sigma, CA, USA) for 7 days prior to functional analysis. Successful infection was confirmed by detecting GFP fluorescence using an inverted fluorescence microscope (Nikon, Tokyo, Japan). Prior to subsequent experiments, the knockdown efficiency of Cx43 shRNAs was validated: Quantitative real-time PCR (qRT-PCR) and Western blotting confirmed that both shCx43-1 and shCx43-2 reduced Cx43 mRNA and protein levels by > 70% (p < 0.01 vs. NTC group), with no significant difference in efficiency between the two (p > 0.05). Preliminary functional assays (cell viability via CCK-8, apoptosis via flow cytometry) further showed consistent attenuation of the Res + CDDP synergistic antitumor effect in both shCx43 groups (p < 0.01 vs. NTC + Res + CDDP group), ruling out off-target effects. Due to its slightly higher knockdown efficiency and lower basal cytotoxicity, shCx43-1 was selected for all subsequent in-depth functional experiments. Cell counting Kit-8 proliferation assay U2-OS cells expressing Cx43 shRNA (shCx43), scrambled shRNA (NTC), or uninfected cells were inoculated into 96-well plates at a final density of 5 × 10³ cells/well and incubated for 24 h. Cells were then treated with different concentrations of resveratrol (Res; 0, 3, 6, 9, 12, 15 µg/ml), cisplatin (CDDP; 0, 1, 3, 6, 9, 12 µg/ml), or their combination (0 + 0, 3 + 1, 6 + 3, 9 + 6, 12 + 9, 15 + 12 µg/ml Res + CDDP) for 48 h. Cell viability was subsequently determined using a Cell Counting Kit-8 (CCK-8) assay (DOJINDO, Kumamoto, Japan) according to the manufacturer’s instructions. Absorbance at 450 nm was measured for each sample using a 96-well plate microplate reader (Thermo Scientific, MA, USA). Cell viability was calculated as follows: Determination of synergy The combined effect of resveratrol (Res) and cisplatin (CDDP) was evaluated using the combination index (CI) as previously described [27]. CI values were calculated via the Chou-Talalay equation using CalcuSyn software version 2.1 (Biosoft). Combination effects were defined as follows: synergistic (CI < 1), additive (CI = 1), or antagonistic (CI > 1). Colony formation assay One hundred U2-OS cells (either expressing Cx43 shRNA [shCx43], scrambled non-targeting control shRNA [NTC], or untreated) were inoculated into each well of 6-well plates and incubated overnight. Cells were then treated with Res, CDDP, or their combination, and cultured for 2 weeks. During this period, cells were refed with corresponding growth medium (with or without drugs) every 2 days. Colonies were fixed with 4% paraformaldehyde for 15 min and stained with 0.5% crystal violet for 15 min. Plates were washed with water, air-dried, and colonies in each well were counted under a microscope. Plating efficiency was calculated as (total number of colonies counted/total number of cells inoculated) × 100%. Cell survival was expressed as the percentage of the plating efficiency of the treated group relative to the control group. DAPI staining U2-OS cells were inoculated into 6-well plates at a density of 2 × 105 cells per well and treated with Res, CDDP, or their combination for 48 h. Cells were rinsed three times with phosphate-buffered saline (PBS), then permeabilized with 0.2% Triton X-100 for 15 min. Nuclei were stained with DAPI (Beyotime, Shanghai, China) for 15 min in the dark. Stained nuclei were observed and photographed using an inverted fluorescence microscope. Apoptosis analysis by flow cytometry U2-OS cells (untreated, expressing shCx43, or NTC) were inoculated into 12-well plates and allowed to attach overnight. Cells were exposed to Res, CDDP, or their combination for 24 h, then collected and resuspended in 400 µl of 1 × binding buffer. A 100 µl aliquot of the cell suspension was transferred to a 5 ml flow tube, mixed with 5 µl Annexin V/Alexa Fluor 647 (Beijing 4 A Biotech Co., Beijing, China), and incubated at room temperature for 5 min in the dark. Subsequently, 10 µl propidium iodide (PI) and 400 µl PBS were added, and fluorescence intensity was immediately analyzed using a BD Accuri C6 flow cytometer (BD, NJ, USA). Measurement of ROS U2-OS cells were inoculated into 6-well plates and incubated overnight. Cells were then exposed to Res, CDDP, or their combination for the indicated times, with or without 5 mM N-acetylcysteine (NAC). Cells were incubated with 2′,7′-dichlorofluorescein diacetate (DCFH-DA) at a final concentration of 10 µM in FBS-free medium for 30 min at 37 °C, then washed three times with PBS. ROS levels were determined using fluorescence microscopy (Nikon, Tokyo, Japan) and flow cytometry (BD Accuri C6, NJ, USA). Wound healing scratch test U2-OS cells were inoculated into 6-well plates and incubated for 24 h to reach confluence. A 200 µl pipette tip was used to create a uniform scratch. Medium was discarded, and cells were rinsed twice with PBS. Cells were then treated with Res, CDDP, or their combination for 48 h in medium containing 2% FBS (to minimize the influence of cell proliferation). Cell migration was observed and photographed under an inverted microscope. Scratch areas were measured using ImageJ software, and migration capacity was calculated as: where D0h = scratch width at 0 h, Dth = scratch width at the indicated time point. Transwell invasion assay U2-OS cells were starved in serum-free medium for 24 h, then resuspended in serum-free medium containing Res, CDDP, or their combination at a density of 3 × 105 cells/ml. A 100 µl aliquot of the cell suspension was added to the upper chamber of Matrigel-precoated Transwell inserts (BD, NJ, USA), while the lower chamber was filled with 600 µl of medium containing 20% FBS (as a chemoattractant). After 24 h of incubation, non-invaded cells in the upper chamber were carefully removed with sterile swabs. Invaded cells were fixed with 4% paraformaldehyde for 20 min, stained with 0.5% crystal violet for 15 min, and rinsed three times with PBS. Five random fields per group were selected under an inverted microscope, and the number of cells that traversed the Matrigel layer was counted at 200×magnification. Quantitative real-time reverse transcription-PCR (qRT-PCR) U2-OS cells were inoculated into 6-well plates and incubated overnight, then exposed to Res, CDDP, or their combination for 48 h. Total RNA was extracted using an RNA extraction kit (TaKaRa, Shiga, Japan) according to the manufacturer’s instructions, and RNA concentration was determined with a SmartSpec Plus spectrophotometer (BIO-RAD, CA, USA). First-strand cDNA was synthesized from 1000 ng of total RNA in a 20 µl reaction volume using PrimeScript RT Master Mix (TaKaRa, Shiga, Japan). qRT-PCR was performed in a 25 µl reaction volume with SYBR Premix Ex Taq (TaKaRa, Shiga, Japan) using a CFX96 QPCR Detection System (BIO-RAD, CA, USA). Primer sequences are listed in Table 1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control, and relative gene expression levels were calculated using the 2-ΔΔCt method. Each experiment was performed at least three times independently. Table 1PCR primer sequences for quantitative real-time PCRGene (GenBank Accession)Forward primer sequenceReverse primer sequencebpCx43(NM_010288.3)GGGTGACTGGAGCGCCTTAGTTATCTCAATCTGCTTCAAG156E- cadherin(NM_009864.3)GCCGCTGGCGTCTGTAGGAATGACCACCGCTCTCCTCCGA112β-Catenin (NM_007614.4)AAAATGGCAGTGCGTTTAGTTTGAAGGCAGTCTGTCGTA185c-Myc (NM_010849.4)CCACACATCAGCACAACTACGCCGCAACAAGTCCTCTTCAG154Cyclin D1(NM_007631.3)TCGGGAGAGGATTAGGTTCCGTCACTGGATGGTTTGTTGG160MMP-2 (NM_008610.3)GACCACAGCCAACTACGATGCACAGTCCGCCAAATGAAC148MMP-9(NM_013599.4)CATCGTCATCCAGTTTGGTGTAGGGTTTCCCATCAGCATT170Bcl-2(NM_009741.5)GTGGAGGAGCTCTTCAGGGAAGGCACCCAGGGTGATGCAA184Bax(NM_001411995.1)TTGCTTCAGGGTTTCATCCACAGCCTTGAGCACCAGTTTG138GAPDH(NM_001411844.1)CCCTTCATTGACCTCAACTACCCACCTTCTTGATGTCATCAT110 PCR primer sequences for quantitative real-time PCR Cx43 (NM_010288.3) E- cadherin (NM_009864.3) Cyclin D1 (NM_007631.3) MMP-9 (NM_013599.4) Bcl-2 (NM_009741.5) Bax (NM_001411995.1) GAPDH (NM_001411844.1) Western blot analysis U2-OS cells were inoculated into 6-well plates and incubated overnight, then exposed to Res, CDDP, or their combination for 48 h. Total protein was extracted with RIPA lysis buffer (Beyotime, Shanghai, China) supplemented with 1% (v/v) protease inhibitor cocktail (Bimake, TX, USA) according to the manufacturer’s protocol. Protein concentration was measured using a BCA Kit (Beyotime, Shanghai, China). Samples were mixed with 5×sodium dodecyl sulfate (SDS) loading buffer (1:4 ratio), boiled for 10 min, and stored at −80 °C. Equal amounts of protein were separated by 8–10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, MA, USA). Membranes were blocked with 5% non-fat milk for 1 h at room temperature, then incubated overnight at 4 °C with the following primary antibodies (1:1000 dilution): rabbit anti-Cx43, anti-E-cadherin, anti-β-catenin, anti-active β-catenin, anti-c-Myc, anti-cyclin D1, anti-MMP-2, anti-MMP-9, anti-Bcl-2, anti-Bax (Cell Signaling Technology, MA, USA), and anti-GAPDH (Panera, Guangzhou, China). GAPDH served as the internal control for total protein. Membranes were then incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody (1:10,000 dilution; Jackson, PA, USA). Protein bands were visualized using an enhanced chemiluminescence (ECL) reagent (Thermo Scientific, MA, USA), imaged with a Bio-Rad ChemiDoc-XRS + system (BIO-RAD, CA, USA), and analyzed using Image Lab software (BIO-RAD, CA, USA). Statistical analysis Data are presented as the mean ± standard deviation (SD) of three independent experiments and were analyzed using SPSS 19.0 software (SPSS Inc., IL, USA). Statistical significance was determined using Student’s two-tailed t-test, one-way analysis of variance (ANOVA), or two-way ANOVA, as appropriate. A p-value < 0.05 was considered statistically significant. Results Cytotoxicity of Res and CDDP in human osteosarcoma U2-OS cells We first evaluated the antitumor effect of resveratrol (Res) combined with cisplatin (CDDP) in U2-OS osteosarcoma cells. Cells were treated with different concentrations of Res, CDDP, or their combination for 48 h, and cell viability was determined (Fig. 1A). When exposed to Res (9 µg/ml), CDDP (6 µg/ml), or the combination, cell viability was 60.1 ± 6.4%, 65.2 ± 6.7%, and 25.3 ± 2.6%, respectively—indicating that combination therapy reduced cell viability to a greater extent than either agent alone. To verify synergism, combination index (CI) values were calculated using the Chou-Talalay method. All combined concentrations of Res and CDDP yielded CI < 1, confirming a significant synergistic effect (Fig. 1B). The combination of 9 µg/ml Res and 6 µg/ml CDDP was selected for subsequent experiments. Combined cytotoxicity of resveratrol (Res) and cisplatin (CDDP) in U2-OS cells. A Survival fractions of U2-OS cells treated with Res, CDDP, or their combination for 48 h. B Combination index (CI) values calculated from proliferation inhibition rates at different Res and CDDP concentrations. C Colony formation of U2-OS cells following treatment with Res, CDDP, and/or their combination. D Cloning efficiencies of each group. Data are presented as mean ± standard error of the mean (SEM) from three independent experiments (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. *p < 0.05, **p < 0.01, vs. Res + CDDP To explore long-term synergistic antitumor effects, a colony formation assay was performed. Combination treatment strongly inhibited colony formation, whereas monotherapy had considerably weaker effects (Fig. 1C). Colony formation rates relative to the control group were 52.3 ± 5.1% (Res), 48.5 ± 4.9% (CDDP), and 15.3 ± 1.4% (combination; Fig. 1D), demonstrating that combined Res + CDDP exerts a sustained synergistic inhibitory effect on U2-OS cell survival and proliferation. Res and CDDP in combination results in enhanced ROS-dependent apoptosis in human osteosarcoma cells To confirm the synergistic cytotoxic effect, U2-OS cell apoptosis was monitored after 48 h of treatment with Res (9 µg/ml), CDDP (6 µg/ml), or their combination. Under bright-field microscopy, the combination group showed fewer total and necrotic cells compared with single-drug groups; additionally, cells in the Res and combination groups exhibited a morphological shift from elliptical to spindle-shaped (Fig. 2A). Flow cytometry with Annexin V (AV)-propidium iodide (PI) staining revealed apoptotic fractions of 27.0 ± 2.7% (control), 39.1 ± 4.0% (Res), 39.2 ± 4.2% (CDDP), and 68.7 ± 6.9% (combination; Fig. 2C), indicating that the combination enhances apoptosis compared with monotherapy. Res and CDDP combination enhances reactive oxygen species (ROS)-dependent apoptosis in U2-OS cells. A Cellular morphological changes induced by Res, CDDP, and/or their combination (bright-field microscopy; magnifications: 40×, 100×, 200×). Apoptotic nuclear morphological changes were detected by DAPI staining (fluorescence microscopy; magnification: 400×). B ROS production in U2-OS cells treated with Res, CDDP, and/or their combination for 3–48 h, measured by DCFH-DA staining and flow cytometry. C, D Apoptosis analysis of U2-OS cells by Annexin V/propidium iodide (PI) flow cytometry. E, F ROS generation in U2-OS cells pretreated with 5 mM N-acetylcysteine (NAC) for 2 h followed by Res, CDDP, and/or their combination for 48 h. E DCFH-DA fluorescence intensity; F quantitative analysis of flow cytometry data. G-I mRNA and protein expression levels of Bcl-2 and Bax in U2-OS cells pretreated with 5 mM NAC for 2 h followed by Res, CDDP, and/or their combination for 48 h, analyzed by quantitative real-time PCR (qRT-PCR) and Western blotting. Data are presented as mean ± SEM from three independent experiments (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *p < 0.05, **p < 0.01, vs. Res + CDDP DAPI staining (400×magnification) showed extensive nuclear condensation and fragmentation (white arrows, Fig. 2A) in the combination group, whereas other treatments did not induce obvious nuclear morphological changes—further confirming higher apoptosis in the combined treatment group. Since reactive oxygen species (ROS) are critical for apoptosis induction, ROS levels were measured using DCFH-DA. The combination group exhibited markedly increased ROS levels in a time-dependent manner compared with other groups (Fig. 2B). Pretreatment with the antioxidant N-acetyl-L-cysteine (NAC) protected U2-OS cells from Res + CDDP-induced cytotoxicity (Fig. 2C and F). Additionally, qRT-PCR and Western blot analysis showed that Bcl-2 (anti-apoptotic) expression was lower in the combination group than in monotherapy groups, whereas Bax (pro-apoptotic) expression was higher—changes that were abrogated by NAC pretreatment (Fig. 2G and I). Collectively, these results demonstrate that Res + CDDP induces greater apoptosis via ROS production. Res and CDDP synergistically inhibit migration and invasion of U2-OS cells Wound-healing and Transwell invasion assays were used to assess the inhibitory effects of drugs on cell migration and invasion in vitro. In the wound-healing assay, cell migration was more strongly inhibited in drug-treated groups than in the control group, with the combination group showing the greatest inhibition (Fig. 3A and B, p < 0.01). In the Transwell invasion assay, drug treatment significantly reduced the number of U2-OS cells invading through the Matrigel layer, and the combination group exhibited the strongest inhibitory effect (Fig. 3C and D, p < 0.01). Res and CDDP synergistically inhibit migration and invasion of U2-OS cells. A, B Migration of U2-OS cells treated with Res, CDDP, and/or their combination (wound-healing assay). C, D Invasion of U2-OS cells treated with Res, CDDP, and/or their combination (Transwell assay). E–G mRNA and protein expression levels of E-cadherin, matrix metalloproteinase (MMP)−2, and MMP-9, analyzed by qRT-PCR and Western blotting. Data are presented as mean ± SEM from three independent experiments (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *p < 0.05, **p < 0.01, vs. Res + CDDP To explore the underlying mechanism, we analyzed the expression of E-cadherin (a migration/invasion suppressor) and matrix metalloproteinases (MMP-2, MMP-9; invasion promoters). qRT-PCR and Western blot results showed that the combination group had the lowest MMP-2 and MMP-9 expression and the highest E-cadherin expression among all groups (Fig. 3E and G). Upregulation of Cx43 is a key component in the ability of combined therapy to exert greater anticancer activity on osteosarcoma cells Previous studies have shown that Cx43 upregulation suppresses malignancy in many tumors [20, 21], prompting us to investigate its role in Res + CDDP synergism. qRT-PCR and Western blot analysis revealed that Cx43 mRNA and protein expression were significantly increased in the Res + CDDP combination group (Fig. 5A and C), which was attributed to Res treatment. Res + CDDP combination inhibits β-catenin and its downstream genes via Cx43. A–C mRNA and protein expression levels of Cx43, β-catenin, c-Myc, and cyclin D1 in U2-OS cells treated with Res, CDDP, and/or their combination, analyzed by qRT-PCR and Western blotting. Data are presented as mean ± standard deviation (SD) from three independent experiments. *p < 0.05, **p < 0.01 vs. Res + CDDP group. D–F mRNA and protein expression levels of Cx43, β-catenin, c-Myc, cyclin D1, MMP-2, MMP-9, and E-cadherin in shCx43 or NTC-expressing U2-OS cells treated with Res + CDDP for 48 h, analyzed by qRT-PCR and Western blotting. Data are presented as mean ± SEM from three independent experiments (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *p < 0.05, **p < 0.01 vs. NTC + Res + CDDP group. *p < 0.05, **p < 0.01, vs. Res + CDDP To confirm Cx43’s role, U2-OS cells with stable Cx43 knockdown were established using lentiviral Cx43 shRNA. Cells were infected with lentiviruses at various multiplicities of infection (MOI: 0, 25, 50, 75, 100, 125), and GFP expression was monitored 72 h post-infection (Fig. 4A). An MOI ≥ 100 achieved > 90% GFP-positive cells, but MOI > 100 induced partial cell death; thus, MOI = 100 was selected for subsequent infections, followed by 7-day selection with 1 µg/ml puromycin. qRT-PCR and Western blot confirmed effective Cx43 knockdown (P < 0.01 vs. untreated or scrambled non-targeting control [NTC] shRNA-expressing cells), with no effect of NTC shRNA on Cx43 expression (Fig. 5D and F). Cx43 upregulation is a key mediator of the enhanced anticancer activity of Res + CDDP combination therapy in U2-OS cells. A Fluorescence micrographs of U2-OS cells infected with Cx43 shRNA lentivirus at different multiplicities of infection (MOI). B Survival of U2-OS cells stably expressing Cx43 shRNA (shCx43) or scrambled non-targeting control (NTC) shRNA following Res + CDDP treatment. C Colony formation of shCx43 or NTC-expressing U2-OS cells treated with Res, CDDP, and/or their combination. D Cloning efficiencies of each group. E, F Apoptosis analysis of shCx43 or NTC-expressing U2-OS cells by Annexin V/PI flow cytometry. G, H Migration of shCx43 or NTC-expressing U2-OS cells treated with Res + CDDP (wound-healing assay). I, J Invasion of shCx43 or NTC-expressing U2-OS cells treated with Res + CDDP (Transwell assay). Data are presented as mean ± SEM from three independent experiments (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *p = 0.032 vs. NTC + Res + CDDP group. *p < 0.05, **p < 0.01, vs. Res + CDDP Cx43 knockdown (shCx43) or NTC cells were treated with Res + CDDP for 48 h. Cx43 knockdown reduced both short-term (cell viability) and long-term (colony formation) cytotoxicity of Res + CDDP (Fig. 4B and D). Flow cytometry showed that Cx43 knockdown also decreased Res + CDDP-induced apoptosis (Fig. 4E and F). Similarly, the inhibitory effects of Res + CDDP on cell migration (Fig. 4G and H) and invasion (Fig. 4I and J) were attenuated by Cx43 knockdown. These data indicate that Res + CDDP exerts enhanced anticancer activity in osteosarcoma via Cx43 upregulation. Res and CDDP in combination inhibit the expression of Wnt/β-catenin and corresponding downstream genes: a key role for Cx43 Abnormal activation of the Wnt/β-catenin pathway contributes to the pathogenesis of many cancers [25]. We found that Res + CDDP downregulated Wnt/β-catenin-related genes, including β-catenin, c-Myc, cyclin D1, MMP-2, and MMP-9 (Figs. 3E and G and 5A and C). To explore the correlation between Cx43 and Wnt/β-catenin signaling, shCx43 or NTC cells were treated with Res + CDDP for 48 h. Cx43 knockdown reversed the Res + CDDP-mediated downregulation of Wnt/β-catenin-related genes (Fig. 5D and F). These results demonstrate that Res + CDDP inhibits the Wnt/β-catenin pathway primarily through Cx43 upregulation. Discussion This study presents novel findings that resveratrol (Res) enhances the antitumor efficacy of cisplatin (CDDP) in osteosarcoma via modulation of the ROS-Cx43-β-catenin axis. While the combination of Res and CDDP has been explored in other cancer types, to our knowledge, this is the first report demonstrating the mechanistic involvement of connexin 43 (Cx43) upregulation in mediating the synergistic effect of Res and CDDP in osteosarcoma. Our data reveal that the combination of Res and CDDP not only enhances ROS production and apoptotic signaling but also restores Cx43 expression—an effect that appears essential for suppressing β-catenin signaling. Mechanistically, Res and CDDP synergistically inhibit U2-OS cell proliferation (validated via the Chou-Talalay method), enhance apoptosis (marked by an increased Bax/Bcl-2 ratio), and suppress migration/invasion (as shown in wound-healing and Transwell assays) [30–32]. The pro-apoptotic effect is ROS-dependent, as pretreatment with the ROS scavenger N-acetylcysteine (NAC) abrogates the cytotoxicity of the combined treatment [10, 11, 33]. Cx43, a critical regulator of intercellular communication, is upregulated by Res; its knockdown attenuates the inhibitory effects of combined treatment on proliferation, migration, and invasion [17, 20, 22, 23, 34, 35]. Concurrently, the Res/CDDP combination suppresses the Wnt/β-catenin pathway, reducing levels of β-catenin, c-Myc, cyclin D1, and matrix metalloproteinases (MMP-2/MMP-9)—effects that are blunted when Cx43 is depleted [36–39]. Importantly, the functional dependence of β-catenin activity on Cx43 expression aligns with recent studies in osteosarcoma and other cancer models. For instance, studies have demonstrated a negative correlation between Cx43 and Wnt/β-catenin pathway activity in U2-OS and colon cancer cells [40, 41]. These findings link Cx43 restoration to the downstream inhibition of oncogenic signaling—a relationship previously unreported in osteosarcoma. This integrated mechanism—linking ROS generation, Cx43 upregulation, and Wnt/β-catenin inhibition—represents a novel therapeutic axis, distinct from prior studies focusing solely on Res’antioxidative properties or CDDP resistance mechanisms. By highlighting Cx43 as a pivotal mediator of synergistic cytotoxicity, our study provides a rationale for targeting gap junction proteins to enhance chemosensitivity, particularly in overcoming CDDP resistance driven by ROS dysregulation and β-catenin hyperactivation [3, 10, 11]. In conclusion, we propose that Res enhances the therapeutic efficacy of CDDP through a novel ROS-Cx43-β-catenin regulatory axis. These findings offer a new perspective for osteosarcoma therapy, particularly in designing combination strategies to improve the clinical outcomes of cisplatin-based chemotherapy. Conclusion Resveratrol enhances the antitumor efficacy of cisplatin in osteosarcoma cells through modulation of the ROS-Cx43-β-catenin signaling axis. All findings are based on in vitro experiments, and the mechanistic link involving Cx43 upregulation is critical to the synergistic cytotoxic effect. While these results provide a promising foundation for understanding redox-sensitive pathways in chemoresistance, further in vivo validation is required before clinical translation can be considered. Acknowledgements The authors would like to thank the students, staff and other lab members who participated in discussions, as well as helped and commented on this study. Author contributions Xue-Dong Li and Shi-Xin Du are corresponding author and organized the study. Hong-Bo Xing, Gui-Zhou Zheng and Xiang Wu analyzed the data. Lei Zhai, Qi-Hao Zhang and Hao-Yu Li performed experiments. Hong-Bo Xing, Qi-Hao Zhang and Gui-Zhou Zheng drafted the manuscript. All authors read and approved the final manuscript. Funding The study was supported by the Science and Technology Research and Development Foundation of Shenzhen (JCYJ20190812171411416, JCYJ20210324131405016, JCYJ20230807142814031), the Department of Education, Guangdong Government, under the Top-Tier University Development Scheme for Research and Control of Infectious Diseases (2015092, 2016011), the Natural Science Foundation of Guangdong Province, China (2014A030313467), and Medical Science and Technology Research Foundation of Guangdong Province, China(A2018523). Data availability All data generated or analyzed during this study are included either in this article and its supplementary information files. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Hao-Yu Li, Gui-Zhou Zheng and Qi-Hao Zhang contributed equally as co-first authors. Change history 9/1/2026 A Correction to this paper has been published: https://doi.org/10.1007/s12672-026-05187-7 Contributor Information Shi-Xin Du, Email: dsx1232013@sina.com. Xue-Dong Li, Email: xuedonglidr@163.com. References Associated Data Data Availability Statement All data generated or analyzed during this study are included either in this article and its supplementary information files.